Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
By K. Fujitani, Han-Kwang Yang, J. Mizusawa, Young-Woo Kim, M. Terashima, Sang-Uk Han, Y. Iwasaki, W. Hyung, A. Takagane, D. Park and 9 more. The Lancet Oncology, 2016
607 citations recorded by the source corpus.
Subfields: Epidemiology, Gastroenterology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/58dfd6e37c4676711e4dcade35a50a720a2d35a6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, background): “However, an international cooperative randomized controlled trial (REGATTA, JCOG0705/KGCA01) failed to prove survival benefit of reduction surgery [4].”
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, background): “(Additional comments in this English edition) No evidence in support of reduction surgery was found in an international cooperative randomized controlled trial (REGATTA, JCOG0705/KGCA01 [3]).”